MIMO Biosciences — Seed

Sanitas, Gutinver and other private investors became shareholders of MIMO Biosciences through a capital increase; the amount was not disclosed. The Cima Universidad de Navarra spin-off, operating since February 2024, develops preclinical animal models reproducing genetic alterations of haematological cancers such as multiple myeloma and lymphoma.